Earned $9 million milestone upon U.S. Food and Drug Administration’s approval of Day One’s OJEMDA™...
Organon, a global women’s healthcare company, initiated XACIATO™ commercial activities in the fourth quarter of...
XOMA is entitled to a mid-single digit royalty on global OJEMDA™ sales First and only FDA-approved type II RAF...
EMERYVILLE, Calif., April 03, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA) (“XOMA” or the...
EMERYVILLE, Calif., March 21, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA) (“XOMA” or the...
EMERYVILLE, Calif., March 19, 2024 (GLOBE NEWSWIRE) -- As previously announced on February 16, 2024, XOMA...
Raised up to $140 million of non-dilutive non-recourse capital through a royalty-backed loan related to...
EMERYVILLE, Calif., Feb. 28, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA), the biotech royalty...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.